StreetInsider.com News Articles

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Fortress Biotech Inc. (NASDAQ: FBIO) announced that its majority-owned subsidiary Cyprium Therapeutics Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds.

The voucher was issued following FDA approval of ZYCUBO (copper histidinate) on January 12, 2026, a treatment for Menkes disease in pediatric patients. Sentynl Therapeutics Inc. assumed responsibility for ZYCUBO's development and commercialization from Cyprium in December 2023, with the voucher immediately transferred to Cyprium upon FDA approval.

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

Fortress Biotech unit to sell rare disease voucher for $205 million

Mon, 23 Feb 2026 09:24:33 -0500

Under the arrangement with Sentynl, Cyprium remains eligible to receive tiered royalties on ZYCUBO net sales and up to $129 million

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of $205 million upon the closing of the transaction.

In December 2023, Sentynl Therapeutics, Inc. (“Sentynl”) assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration (“FDA”)

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Mon, 23 Feb 2026 09:24:00 -0500